Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Chicago
University of Chicago
City of Hope Medical Center
Hospital of Stomatology, Wuhan University
University of Chicago
University of Chicago
University Medical Center Groningen
Presage Biosciences
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Arbeitsgemeinschaft medikamentoese Tumortherapie
Glycotope GmbH
UNICANCER
UNICANCER
Washington University School of Medicine
AstraZeneca
Wake Forest University Health Sciences
Celgene
Groupe Oncologie Radiotherapie Tete et Cou
Amgen
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Massachusetts General Hospital
University of Miami
Lithuanian University of Health Sciences
University of Leipzig
Merck KGaA, Darmstadt, Germany
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Fudan University
Groupe Oncologie Radiotherapie Tete et Cou
SWOG Cancer Research Network
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris